logo
Plus   Neg
Share
Email

Boehringer, Lilly Report Positive Top-line Phase III Empagliflozin Results

Boehringer Ingelheim and Eli Lilly and Co. (LLY) announced top-line results for four completed Phase III trials for empagliflozin, an investigational sodium glucose co-transporter-2 or SGLT-2 inhibitor being studied for type 2 diabetes or T2D treatment.

The company said that incidence of adverse events was similar for placebo, empagliflozin 10mg and 25mg, while genital infections occurred more often with empagliflozin compared with placebo. This safety information is consistent with findings reported in the Phase II trial results for empagliflozin.

Empagliflozin is being investigated in adults with T2D in a Phase III study program, which would enroll more than 14,500 patients. Totally, this program consists of eight multinational trials, including a large cardiovascular outcome trial. The pivotal studies for empagliflozin completed in 2012, and Boehringer Ingelheim and Lilly anticipate filing for regulatory review in the U.S., Europe and Japan in 2013. Boehringer Ingelheim and Lilly intend to present detailed data disclosures for many of these studies at scientific medical meetings and publications in 2013 and 2014.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Facebook has removed four separate networks of accounts, pages and groups for engaging in co-ordinated inauthentic behavior on Facebook and Instagram. These networks originated from Iran and Russia and primarily targeted the US, North Africa and Latin America. These networks often posted on both sides of political issues including topics like US elections, environmental issues, racial tensions. While reporting financial results for the third quarter on Tuesday, Lockheed Martin Corp. (LMT) raised its earnings and net sales guidance for the full-year 2019, and initiated net sales outlook for the full-year 2020. For fiscal 2019, the company now expects earnings of about $21.55 per share, up... Consumer goods giant Procter & Gamble on Tuesday reported a 12 percent increase in profit for the first quarter of fiscal 2020 from last year, driven by an increase in net sales and operating margin. Both revenue and core earnings per share for the quarter beat analysts' estimates. Looking ahead, the company raised its earnings and revenue growth guidance for the full-year 2020.
Follow RTT
>